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Abstract 
 
 
Objective 
Plasma glycated CD59 (pGCD59) is an emerging biomarker in diabetes. We assessed 
whether pGCD59 could predict: the results of the glucose challenge test (GCT) for 
screening of gestational diabetes (GDM) (primary analysis); and the diagnosis of GDM and 
prevalence of large for gestational age (LGA) newborns (secondary analyses).  
 
Research Design and Methods 
Case-control study of 1,000 plasma samples from women receiving standard prenatal care: 
500 with a normal GCT (controls) and 500 with a failed GCT and a subsequent OGTT 
(cases).  
Results 
Compared to controls, median pGCD59 was 8.5-fold higher in cases and 10-fold higher in 
GDM; median (IQR): controls: 0.33 (0.19); cases: 2.79 (1.4); GDM 3.23 (1.43) (p<0.001); 
AUROCs: 0.92. LGA prevalence was 4.3% in the lowest and 13.5% in the highest quartiles 
of pGCD59.  
Conclusion 
One pGCD59 measurement at week 24-28 identifies pregnancy-induced glucose 
intolerance with high sensitivity and specificity and can potentially identify risk for LGA. 
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Screening for Gestational Diabetes (GDM) with an oral glucose challenge test (GCT) is a 
standard of care for all non-diabetic pregnant women (1; 2) because the adverse 
pregnancy outcomes associated with GDM can be mitigated with appropriate therapy (3; 
4). Screening (GCT) and diagnosis glucose tolerance tests (OGTT) are time consuming, 
uncomfortable and have poor reproducibility (5). Other tests such as HbA1c or 
fructosamine are not routinely measured during pre-natal care because of their low 
sensitivity and specificity to identify women at risk of GDM (6; 7). 
The complement system and its regulators reportedly play a role in the pathogenesis of 
diabetes complications (8). In diabetes, non-enzymatic glycation inactivates the 
complement inhibitor CD59, forming glycated CD59 (GCD59) (9). Using a sensitive and 
specific ELISA for GCD59 in blood, we have shown that plasma GCD59 (pGCD59) levels 
are significantly higher in individuals with type 2 diabetes, and independently predict the 
response to OGTT (10).  
Our primary objective was to assess the accuracy of pGCD59 in predicting the results of 
the GCT. As secondary aims we assessed the accuracy of pGCD59 in predicting the 
diagnosis of GDM by OGTT, and explored the association of pGCD59 with the prevalence 
of large for gestational age (LGA) newborns at delivery.  
RESEARCH DESIGN AND METHODS 
We performed a case-control study measuring pGCD59 in 1,000 samples from 
women undergoing routine two-step gestational diabetes screening and diagnosis at 
Brigham and Women’s Hospital (BWH; 2012-2014). Two sets of 500 samples each 
were collected randomly from women that either passed the 50-gram GCT and 
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therefore did not undergo 3hr-OGTT (controls) or failed the GCT and therefore 
underwent standard of care 100-grams, 3-hr OGTT (cases) at BWH. Pregnancy week 
at sample collection was the same for controls and cases (26.5 ± 3.3 and 26 ± 1.8, 
respectively). Samples for pGCD59 measurement were separated from the same 
tubes used to measure plasma glucose and stored (-80°C) by Partners’ Crimson 
Biorepository Core (CBC)(10), a clinical investigation facility that anonymously 
collects discarded materials from the clinical laboratories of Partners Healthcare 
Hospitals. Medical information was retrieved from electronic records before samples 
were de-identified; only coded samples were delivered for pGCD59 measurement. 
pGCD59 was measured using the specific ELISA described in (11); test operators 
were blind to the women’s glucose status. Inter-assay coefficient of variation was 
<10.0%. Partners Healthcare IRB approved this study (Protocol: 
2011P002254/BWH). We followed STARD guidelines for study design and reporting. 
Statistical analysis 
Patients’ characteristics were described using medians and interquartile ranges for 
continuous variables and count proportions for categorical variables. Sensitivity and 
specificity of pGCD59 to predict the results of the GCT were assessed using non-
parametric estimates of the receiver operating characteristic (ROC) curves and respective 
area under the curve (AUROC)(12). Positive and negative predictive values (PPV and 
NPV) and positive likelihood ratio (LR+) were calculated as in (13). Following WHO 
recommendations, LGA was defined as ≥90th percentile birth weight adjusted for 
gestational age at delivery and determined from the latest gender-specific reference 
curves derived from a large sample that reflects the ethnic distribution of the US 
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population(14). Statistical analyses were performed using Stata software, version 13.1 
(Statacorp, College Station, TX, USA). 
RESULTS 
Among the 500 cases, 127 met Carpenter and Coustan (C&C) criteria for GDM(15). 
Supplementary Table 1 summarizes maternal and infant characteristics; the ethnic/racial 
composition of the women was comparable to that of the United States(14).  Median 
pGCD59 levels were: 8.5-fold higher in the 500 cases than in the 500 controls and 10-fold 
higher in the 127 cases diagnosed with GDM by 3hr-OGTT (Figure 1, Supplementary 
Figure 1 and Supplementary Table 2). The probability density function (Figures 1A and 1B) 
and AUROCs (Figures 1C and 1D) show that pGCD59 independently discriminated cases 
from controls with high sensitivity and specificity, even after adjustment for covariates such 
as maternal age, BMI, race/ethnicity, multiplicity, gestational age and previous history of 
diabetes (adjusted AUROC controls vs. cases = 0.92, 95%CI: 0.88, 0.93; adjusted 
AUROCs controls vs. GDM = 0.92, 95%CI: 0.87, 0.96). PPV and NPV for the overall 
distribution of GCD59 values to identify cases were 99.3% (95%CI: 97.9, 99.8) and 87.5% 
(95%CI: 84.5, 90.1); and 99.1% (95%CI: 94.9, 99.9) and 95.6% (95%CI: 93.8, 97.4) to 
identify women with GDM. Women with pGCD59 values ≥ 6th decile had a likelihood of 
having a failed GLT 8-fold higher than for those below the 6th decile (LR+ 7.97 
Supplementary Table 3).  
Among the 852 singletons who had recorded birth weight and gender, 86 (10%) were 
identified as LGA, 28 born to controls and 58 to cases (Supplementary Table 1). Higher 
maternal pGCD59 was associated with a higher prevalence of LGA, which was 4.3% 
(9/207) in the lowest and 13.5% (29/214) in the highest quartile of pGCD59 (chi-square p-
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value = <0.0001; Supplementary Figure 2). This result was not affected by adjustment for 
maternal age, race/ethnicity and BMI. Notably, 45/58 (78%) LGA infants in the case 
population were born to mothers who did not meet C&C OGTT threshold criteria for GDM 
but had median pGCD59 values 7-fold higher than controls (Supplementary Table 4).  
CONCLUSION 
This study explored the clinical utility of pGCD59 to screen/diagnose GDM. One 
maternal pGCD59 measurement at a mean gestational week ≈26 predicted the 
results of the GCT with high sensitivity and specificity and independently of 
covariates such as age, BMI, race/ethnicity, multiplicity, gestational age and previous 
history of diabetes (Figure 1, Supplementary Figure 1).  Median pGCD59 values were 
progressively higher across the categories of maternal glucose tolerance 
(Supplementary Table 2). These findings indicate that pGCD59 potentially represents 
a convenient and effective alternative to the cumbersome glucose challenge methods 
currently used to screen/diagnose GDM.   
Glucose challenge tests fail to recognize the continuous association between maternal 
hyperglycemia and abnormal pregnancy outcomes, and exclude milder forms of glucose 
intolerance that may still impart perinatal risk (16; 17). The progressively higher pGCD59 
levels observed across the GCT-OGTT categories (Supplementary Table 2) suggest that 
pGCD59 may reflect the continuum of pregnancy-induced glucose intolerance described 
by the HAPO study(16).   
pGCD59 levels at gestational week ≈26  were associated with higher prevalence of LGA at 
birth. Among cases, 22% of LGA newborns were born to women diagnosed with GDM 
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while 78% were born to women that failed the GCT but did not meet C&C criteria for GDM. 
This likely reflects the effect of treatment on women with formal diagnosis of GDM, and is 
consistent with conclusions of the HAPO and other studies showing that women in an 
intermediate category between “normal” and “abnormal” glucose tolerance are at higher 
risk of abnormal pregnancy outcomes(18). Currently, there are no guidelines for the 
management of women in the “intermediate” category and, therefore, their management is 
the same as that of women with a normal GCT. The fact the 45 cases who did not meet 
C&C criteria for GDM but delivered LGA newborns had median pGCD59 levels 7-fold 
higher than controls provides additional evidence for the potential clinical utility of pGCD59 
for screening/diagnose GDM (16). 
Limitations: a) the study was observational, b) clinical and demographic characteristics 
were limited to those available in medical records, c) we could not adjust for the time of day 
when GCT was performed since all testing was done per routine clinical care (19),  d) the 
study was not aimed at establishing a clinically useful cut-off value or assessing how 
pGCD59 measures might influence clinical care in real-time, the impact of treatment on the 
prevalence of LGA.  
In summary, this is the first study showing that a single measurement of pGCD59 at 
gestational week ≈26 represents a simplified method to identify women who would have 
failed a GCT, are at higher risk of GDM and possibly of having an LGA newborn. Validation 
of pGCD59 as a biomarker for detection of pregnancy induced glucose intolerance and 
determination of clinically useful cut off values will require multi-center studies and 
“consensus” expert committees that will take into account relative risks, cost-benefits and 
other individual and public health considerations, as has been the norm with currently used 
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methodologies for screening and diagnosis of GDM. Future studies should also assess 
whether pGCD59 1) similarly classifies pregnant women with normal or abnormal glucose 
tolerance as defined by the 2hr, 75 grams OGTT recommended by the IADPSG, 2) is a 
predictor of adverse outcomes in pregnant women in the intermediary category glucose 
tolerance who might benefit from treatment, and 3) detects glucose intolerance earlier in 
pregnancy than current practice prompting earlier interventions that may mitigate further 
the risks associated with maternal hyperglycemia. 
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FIGURE LEGENDS 
Figure 1. A-B: pGCD59 probability density functions by case-control status and 
between controls vs GDM. Glucose challange tests were adjudicated using ACOG 
guidelines: failed 50-grams GCT > 140mg/dL; 100 grams, 3-hr OGTT: No-GDM: 0 or 1 
abnormal glucose value; GDM: 2+ abnormal glucose values based on Carpenter and 
Coustan criteria (C&C). A: Controls vs. Cases; B: Controls vs. GDM. The red dotted lines 
indicate the median pGCD59 values for the respective groups; the difference in median 
values between two groups and 95% confidence interval are mentioned on the figure (n= 
	 12	
1,000). C-D: ROC curve AUCs by case-control status and controls vs GDM. C: 
Controls vs. Cases; D: Controls vs. GDM. Marginal and conditional ROC curves were computed 
and adjusted for maternal age, BMI, race/ethnicity, multiplicity and gestational age at GCD59 
determination and previous history of diabetes. AUROCs were derived using the DeLong, DeLong 
and Clarke-Pearson non-parametric tied corrected estimator(20) and the percentile values of the 
case observations with respect to the control distribution were used to derive the tied corrected 
estimator(20). Under non-parametric estimation, standard errors and derived AUROCs 95%CI were 
estimated using cross validation and bootstrapping procedures with 1,000 replications. Solid lines: 
unadjusted ROC curves. Dashed lines: ROC curves adjusted for maternal age, 
race/ethnicity, BMI, gestation week at pGCD59 determination and previous history of 
diabetes (n=1,000).  Insets show adjusted AUC, sensitivity and specificity with 95% CI. 
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Supplementary Figure 1. Box/whisker plots showing the distribution 
of pGCD59 values by case-control status (n = 1000): Median and IQR 
values are shown in the figure.
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Supplementary Figure 2
Supplementary Figure 2. Prevalence of LGA by quartiles of 
pGCD59 in the study population.  The Figure shows the prevalence of 
LGA with 95% confidence intervals in parenthesis in the four quartiles 
of pGCD59 (n= 852).  The median pGCD59 values with interquartile 
range (IQR) are shown below each quartile. 
 Supplementary Table 1: Women’s and infant’s socio-demographic and anthropometric 
characteristics, n= 1,000. The race/ethnicity composition of our study population closely 
resembles that of the United States population 
 Controls, 
n(%) 
Cases, n(%) Cases (Failed-GLT), n(%) 
 Normal-
GCT 
Failed-GCT No-GDM GDM  
   OGTT with 
0 abnormal 
value 
OGTT with 1 
abnormal 
value 
  
Maternal 
characteristics 
 
n=500 n=500 n=273 n=100 n=127 p-value* 
Age in 
categories(yr) 
          0.001 
<20 18(3.6) 8(1.6) 5(1.8) 1(1.0) 2(1.6)  
20-29 171(34.2) 119(23.8) 66(24.2) 25(25.0) 28(22.0)  
30-34 174(34.8) 182 (36.4) 106(38.8) 39(39.0) 37(29.1)  
35-39 99(19.8) 140(28.0) 73(26.8) 22(22.0) 45(35.4)  
>40 38(7.6) 51(10.2) 23(8.4) 13(13.0) 15(11.8)  
Race           <0.001 
Asiatic 34(6.8) 55(12.6) 29(11.9) 9(10.5) 17(15.9)  
Black 56(11.3) 57(13.1) 33(13.6) 7(8.1) 17(15.9)  
Hispanic 98(19.7) 132(30.3) 73(30.4) 24(27.9) 35(32.7)  
Others 90(18.2) 3(0.7) 2(0.8) 0(0) 1(0.9)  
White 218(43.9) 189(43.3) 106(43.6) 46(54.5) 37(34.6)  
 BMI at first prenatal 
visit(kg/m2) 
          <0.001 
<19 51(10.3) 42(8.7) 32(11.9) 6(6.5) 4(3.3)  
20-24 229(46.2) 144(29.8) 98(36.6) 21(22.8) 25(20.3)  
25-29 140(28.2) 144(29.8) 66(24.6) 30(32.6) 48(39.0)  
>30 76(15.3) 153(31.7) 72(26.9) 35(38.1) 46(37.4)  
Previous history of 
diabetes 
          0.151 
Yes 2(0.4) 6(1.2) 5(1.9) 0(0) 1(0.8)  
No 489(99.6) 480(98.8) 263(98.1) 97(100) 120(99.2)  
             
Infant 
characterisitics 
           
Large for 
gestational age 
(singleton infants)** 
          0.001 
Yes 28(6.7) 58(13.3) 33(13.8) 12(14.2) 13(11.7)  
No 388(93.3) 378(86.7) 207(86.2) 73(85.8) 98(88.3)  
Gender           0.145 
Male 234(52.1) 254(56.7) 142(57.3) 38(43.2) 62(55.4)  
Female 215(47.9) 194(43.3) 106(42.7) 50(56.8) 50(44.6)  
Multiplicity           0.052 
Yes 18(3.6) 31(6.3) 14(5.2) 6(6.2) 11(8.8)   
No 477(96.4) 459(94.7) 255(94.8) 91(93.8) 113(91.1)   
*Difference of proportions cases vs controls: Chi-square p-value  
**Restricted to only singleton cases and defined as a birth-weight ≥90th percentile 
adjusted for gestational week at delivery and determined from the latest gender-
specific reference curves derived from a large sample of infants reflecting the 
ethnic distribution of the US population   
      
Supplementary Table 2: pGCD59 median, distribution and interquartile range by case 
control status and OGTT sub-groups. n= 1,000 
     
N 
 
Median 
 
IQR 
p-value of 
trend 
          <0.001 
Controls-  
 
Normal-GCT 
  
500 
 
0.33 
 
0.19 
 
Cases- 
Failed-GCT 
  
500 
 
2.79 
 
1.40 
 
 
 
     
 No-GDM 
 
 
    OGTT with 0 
abnormal value 
 
273 
 
2.68 
 
1.31 
  
 
OGTT with1 
abnormal value 
 
100 
 
2.77 
 
1.27 
  
 
 
GDM 
   
127 
 
3.23 
 
1.43 
  
 
 
 
 
Delta Normal-GCT vs Failed-GCT   2.46, 95%CI(2.34, 2.57) p-value <0.001 
Delta Normal-GCT vs GDM      2.9 (2.72, 3.07) p-value <0.001 
Delta Normal-GCT vs OGTT with 1 abnormal value 2.44 95%CI(2.22, 2.65) p-value <0.001 
Delta Normal-GCT vs OGTT with 0 abnormal value 2.33 95%CI(2.2, 2.4) p-value <0.001 
IQR: Interquartile Range 
 
 
Supplementary Table 3: pGCD59 decile cutoffs to predict glucose challenge test 
(GCT) results, n=1,000 
Cutoff 
GD59 
Deciles Sensitivity specificity 
Correctly 
Classify PPV NPV LR+ LR- 
Youden 
Index 
≥5 88.46% 72.20% 80.28% 76.09% 86.22% 3.18 0.16 0.61 
≥6 86.03% 89.20% 87.63% 88.85% 86.46% 7.97 0.16 0.75 
≥7 77.53% 99.80% 88.73% 99.74% 81.62% 387.66 0.23 0.77 
 
Youden index = (sensitivity + specificity) - 1; its value ranges from 0 to 1, and has a zero 
value when a diagnostic test gives the same proportion of positive results for groups with 
and without the disease (i.e., the test is useless).   A value of 1 indicates that there are no 
false positives or false negatives (i.e., the test is perfect). 
Supplementary Table 4: pGCD59 median and interquartile ranges by case control 
status and relevant covariates. n= 1,000 
 Controls, 
n(%) 
Cases, 
n(%) 
Cases (Failed-GLT), n(%)  
 Normal-
GCT 
Failed-GCT No-GDM GDM  
   OGTT with 0 
abnormal value 
OGTT with 1 
abnormal value 
  
Maternal 
characteristics 
 n= 500  n= 500         n=273 n= 100  n= 127 p-
value* 
Age in 
categories(yr)  
          0.025  
<20 0.39 (0.19) 3.48(1.65) 3.08 (0.59) 4.56 (0.00) 4.09 (1.22)  
20-29 0.31 (0.17) 2.78(1.28) 2.74 (1.30) 2.62 (1.07) 3.23 (0.93)  
30-34 0.35 (0.18) 2.65(1.38) 2.57 (1.41) 2.61 (1.12) 3.19 (0.88)  
35-39 0.33 (0.20) 2.95(1.48) 2.76 (1.34) 3.10 (1.13) 3.22 (1.87)  
>40 0.33 (0.21) 2.74 (2.10) 2.53 (1.22) 3.02 (2.96) 3.31 (3.50)  
Race           <0.001 
Asian 0.32 (0.19) 2.77 (1.46) 2.63 (1.14) 2.95 (2.49) 3.01 (2.65)  
Black 0.29 (0.18) 3.09 (1.63) 2.95 (1.14) 1.81 (2.05) 3.54 (0.94)  
Hispanic 0.33 (0.16) 3.03 (1.04) 2.91 (1.05) 2.78 (0.98) 3.34 (0.77)  
Others 0.33 (0.20) 2.75 (3.01) 2.97 (0.43) - 0.17 (0.00)  
White 0.34 (0.19) 2.47 (1.43) 2.23 (1.45) 2.65 (1.14) 2.68 (2.09)  
 BMI at first 
prenatal visit 
(kg/m2) 
          <0.001 
<19 0.28 (0.17) 2.53 (0.94) 2.56 (0.85) 1.98 (2.18) 3.26 (3.24)  
20-24 0.35 (0.20) 2.72 (1.55) 2.54 (1.44) 2.95 (1.33) 3.00 (1.66)  
25-29 0.33 (0.18) 2.92 (1.28) 2.76 (1.17) 2.78 (1.17) 3.31 (1.15)  
>30 0.32 (0.18) 2.78 (1.35) 2.73 (1.43) 2.64 (1.05) 3.22 (1.65)  
Previous history 
of diabetes 
          <0.001 
Yes 1.48 (2.48) 3.05 (0.79) 2.92 (0.57) - 4.00 (0.00)  
No 0.33 (0.19) 2.77 (1.40) 2.68 (1.30) 2.76 (1.24) 3.22 (1.41)  
Infant 
characteristics 
           
Large for 
gestational age** 
          <0.001 
Yes 0.39 (0.21) 2.78(0.93) 2.61 (0.85) 2.73 (1.10) 3.47 (0.34)  
No 0.33 (0.19) 2.77(1.39) 2.68 (1.32) 2.73 (1.26) 3.19 (1.53)  
Gender           0.052 
Male 0.33 (0.20) 2.85 (1.39) 2.72 (1.30) 2.94 (1.41) 3.23 (1.50)  
Female 0.33 (0.18) 2.76 (1.39) 2.61 (1.26) 2.66 (1.11) 3.21 (1.24)  
Multiplicity            0.007 
Yes 0.33 (0.34) 3.00 (1.49) 2.59 (1.34) 3.73 (1.29) 3.30 (1.33)  
No 0.33 (0.18) 2.78 (1.38) 2.68 (1.31) 2.74 (1.24) 3.23 (1.38)  
*Kruskal-Wallis test (complete case analysis) 
**Restricted to only singleton cases 
IQR: Interquartile Range     
      
Median pGCD59 differences according to maternal socio-demographic and anthropometric 
characteristics were assessed using non-parametric tests. 
 
